---
audienceLevel: patient
cancerTypes:
- general
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Elranatamab-bcmm - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/elranatamab-bcmm
version: v1
---

# Elranatamab-bcmm - NCI

# Elranatamab-bcmm

Placeholder slot

(EL-rah-NA-tah-mab)

Elranatamab-bcmm works by bringing healthy T cells (immune cells that help kill cancer cells) and myeloma cells close together so the T cells can more effectively kill the myeloma cells. It does this by binding to a protein called CD3 on healthy T cells and a protein called BCMA on myeloma cells. Elranatamab-bcmm is a type of targeted therapy drug called a bispecific T-cell engager (BiTE).

US Brand Name(s)

Elrexfio

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f6fea598-ff58-4a20-b5e8-8a51f37d8beb&audience=consumer)

## Use in Cancer

Elranatamab-bcmm
is approved to treat:

- **[Multiple myeloma](/Common/PopUps/popDefinition.aspx?id=45793&version=Patient&language=English)** that has come back or did not respond to treatment. It is used in adults who have received at least four previous treatments that included an [immunomodulating agent](/Common/PopUps/popDefinition.aspx?id=739791&version=Patient&language=English), a [proteasome inhibitor](/Common/PopUps/popDefinition.aspx?id=393541&version=Patient&language=English), and an [anti-CD38 monoclonal antibody](/Common/PopUps/popDefinition.aspx?id=798792&version=Patient&language=English).

Elranatamab-bcmm is approved under FDAâ€™s [Accelerated Approval Program](https://www.fda.gov/ForPatients/Approvals/Fast/ucm405447.htm). As a condition of approval, [confirmatory trial(s)](/Common/PopUps/popDefinition.aspx?id=799146&version=Patient&language=English) must show that it provides a clinical benefit in these patients.

Elranatamab-bcmm is only available as part of a special program called Elrexfio REMS ([Risk Evaluation and Mitigation Strategies](https://www.elrexfiorems.com/#Main)).

## More About Elranatamab-bcmm

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/792267) - Detailed scientific definition and other names for this drug.

MedlinePlus Information on [Elranatamab-bcmm](https://medlineplus.gov/druginfo/meds/a623045.html) - A lay language summary of important information about this drug that may include the following:

- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

## Research Results and Related Resources

[Targeted Therapy to Treat Cancer](https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies)

[Monoclonal Antibodies](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Elranatamab-bcmm](https://www.cancer.gov/research/participate/clinical-trials/intervention/C146860) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
